Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Quizartinib in Severe Hepatic Impairment
NCT06740799Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06740799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740799.